I期临床-话题@MedSci

#I期临床#

570篇内容 | 7044人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652998, encodeId=f9e0165299881, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=J Gastroenterology：维多珠单抗对日本克罗恩病患者的疗效影响——III期临床研究 , objectType=article, longId=189573, objectId=89671895e3b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89671895e3b8, replyNumber=0, likeNumber=71, createdTime=2020-10-16, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89671895e3b8, moduleTitle=J Gastroenterology：维多珠单抗对日本克罗恩病患者的疗效影响——III期临床研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89671895e3b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653090, encodeId=a94116530904f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期, objectType=article, longId=201090, objectId=24af2010905f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24af2010905f, replyNumber=0, likeNumber=60, createdTime=2021-01-12, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24af2010905f, moduleTitle=ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24af2010905f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653108, encodeId=ccb21653108b5, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=II期临床：白介素23单抗Mirikizumab持续改善克罗恩病患者症状并减少肠道炎症, objectType=article, longId=202091, objectId=a75320209101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a75320209101, replyNumber=0, likeNumber=83, createdTime=2021-07-18, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a75320209101, moduleTitle=II期临床：白介素23单抗Mirikizumab持续改善克罗恩病患者症状并减少肠道炎症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a75320209101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653026, encodeId=35501653026b0, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=上周获批II期临床后，Moderna新冠病毒mRNA疫苗又获得FDA授予的快速通道指定, objectType=article, longId=194118, objectId=cc4519411845, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc4519411845, replyNumber=0, likeNumber=70, createdTime=2021-01-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc4519411845, moduleTitle=上周获批II期临床后，Moderna新冠病毒mRNA疫苗又获得FDA授予的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc4519411845)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653016, encodeId=9fda16530165e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Merimepodib治疗COVID-19的II期临床试验：即将开始, objectType=article, longId=193035, objectId=ed7619303569, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed7619303569, replyNumber=0, likeNumber=95, createdTime=2020-05-04, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed7619303569, moduleTitle=Merimepodib治疗COVID-19的II期临床试验：即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed7619303569)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652991, encodeId=b51d16529919a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Verona Pharma公布ensifentrine作为慢性阻塞性肺病（COPD）维持治疗的II期临床结果, objectType=article, longId=188170, objectId=28501881e0e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28501881e0e2, replyNumber=0, likeNumber=89, createdTime=2020-03-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28501881e0e2, moduleTitle=Verona Pharma公布ensifentrine作为慢性阻塞性肺病（COPD）维持治疗的II期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28501881e0e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653004, encodeId=6b211653004dd, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展, objectType=article, longId=190693, objectId=7c61190693ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c61190693ac, replyNumber=0, likeNumber=70, createdTime=2020-12-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c61190693ac, moduleTitle=抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c61190693ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653010, encodeId=8e5916530106f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准, objectType=article, longId=191868, objectId=b01e191868d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b01e191868d2, replyNumber=0, likeNumber=60, createdTime=2020-11-24, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b01e191868d2, moduleTitle=OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b01e191868d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652990, encodeId=7755165299015, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功, objectType=article, longId=188050, objectId=0cde18805010, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cde18805010, replyNumber=0, likeNumber=0, createdTime=2020-07-17, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cde18805010, moduleTitle=默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cde18805010)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653063, encodeId=a2a61653063d9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Asunercept治疗COVID-19：已在欧洲及俄罗斯开展II期临床试验, objectType=article, longId=198325, objectId=726b198325ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=726b198325ff, replyNumber=0, likeNumber=58, createdTime=2020-11-09, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=726b198325ff, moduleTitle=Asunercept治疗COVID-19：已在欧洲及俄罗斯开展II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=726b198325ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653061, encodeId=b6df165306160, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=IMU-838联合Oseltamivir治疗中重度COVID-19的II期临床试验：首位患者已入组, objectType=article, longId=198175, objectId=65311981e586, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65311981e586, replyNumber=0, likeNumber=72, createdTime=2021-06-01, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65311981e586, moduleTitle=IMU-838联合Oseltamivir治疗中重度COVID-19的II期临床试验：首位患者已入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65311981e586)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653034, encodeId=092b165303425, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=免疫应答率100%！陈薇院士团队柳叶刀报告全球新冠疫苗I期临床试验结果, objectType=article, longId=194887, objectId=4dff19488e70, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dff19488e70, replyNumber=0, likeNumber=14, createdTime=2021-01-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dff19488e70, moduleTitle=免疫应答率100%！陈薇院士团队柳叶刀报告全球新冠疫苗I期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dff19488e70)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653024, encodeId=508f1653024d7, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=间充质样细胞产品PLX治疗COVID-19：II期临床即将开展, objectType=article, longId=193909, objectId=e6d31939090f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6d31939090f, replyNumber=0, likeNumber=92, createdTime=2020-09-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6d31939090f, moduleTitle=间充质样细胞产品PLX治疗COVID-19：II期临床即将开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6d31939090f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653068, encodeId=7e96165306817, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=阿斯利康的IL-5受体单抗Fasenra：III期临床证实在嗜酸性哮喘中具有强大疗效, objectType=article, longId=198911, objectId=81e1198911ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81e1198911ce, replyNumber=0, likeNumber=71, createdTime=2021-01-24, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81e1198911ce, moduleTitle=阿斯利康的IL-5受体单抗Fasenra：III期临床证实在嗜酸性哮喘中具有强大疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81e1198911ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653001, encodeId=3bf816530015c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet：4价登革热疫苗TAK-003II期临床效果显著, objectType=article, longId=190311, objectId=8fbd190311cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fbd190311cd, replyNumber=0, likeNumber=78, createdTime=2020-08-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fbd190311cd, moduleTitle=Lancet：4价登革热疫苗TAK-003II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fbd190311cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653067, encodeId=6724165306ee3, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=AAIC 2020：II期临床证实重组GM-CSF对阿尔茨海默氏症有治疗潜力, objectType=article, longId=198856, objectId=39521988569d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39521988569d, replyNumber=0, likeNumber=56, createdTime=2020-09-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39521988569d, moduleTitle=AAIC 2020：II期临床证实重组GM-CSF对阿尔茨海默氏症有治疗潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39521988569d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653025, encodeId=384e165302564, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=学术前沿| 天津总医院杨学军团队发现原研新药ACT001抑制胶质瘤生长新机制 II期临床试验将启动, objectType=article, longId=194057, objectId=3dae19405ec5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dae19405ec5, replyNumber=0, likeNumber=71, createdTime=2020-06-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dae19405ec5, moduleTitle=学术前沿| 天津总医院杨学军团队发现原研新药ACT001抑制胶质瘤生长新机制 II期临床试验将启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dae19405ec5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653087, encodeId=5897165308ea4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=挑战25年来的共识！阿尔兹海默症疫苗即将开展III期临床，这家公司剑指tau蛋白阿喀琉斯之踵, objectType=article, longId=200686, objectId=c99d2006862e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c99d2006862e, replyNumber=0, likeNumber=67, createdTime=2021-05-25, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c99d2006862e, moduleTitle=挑战25年来的共识！阿尔兹海默症疫苗即将开展III期临床，这家公司剑指tau蛋白阿喀琉斯之踵, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c99d2006862e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652981, encodeId=f9bc1652981db, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=口服溃疡性结肠炎新药Brilacidin的I期临床试验, objectType=article, longId=186742, objectId=dc09186e42b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc09186e42b5, replyNumber=0, likeNumber=60, createdTime=2020-11-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc09186e42b5, moduleTitle=口服溃疡性结肠炎新药Brilacidin的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc09186e42b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653109, encodeId=a24416531090b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=IDWeek 2020：肺炎链球菌疫苗ASP3772的I期临床数据，即将揭晓, objectType=article, longId=202383, objectId=969620238316, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=969620238316, replyNumber=0, likeNumber=55, createdTime=2021-10-03, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=969620238316, moduleTitle=IDWeek 2020：肺炎链球菌疫苗ASP3772的I期临床数据，即将揭晓, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=969620238316)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

J Gastroenterology：维多珠单抗对日本克罗恩病患者的疗效影响——III期临床研究

2020-10-16

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期

2021-01-12

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

II期临床：白介素23单抗Mirikizumab持续改善克罗恩病患者症状并减少肠道炎症

2021-07-18

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

上周获批II期临床后，Moderna新冠病毒mRNA疫苗又获得FDA授予的快速通道指定

2021-01-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Merimepodib治疗COVID-19的II期临床试验：即将开始

2020-05-04

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Verona Pharma公布ensifentrine作为慢性阻塞性肺病（COPD）维持治疗的II期临床结果

2020-03-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展

2020-12-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准

2020-11-24

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功

2020-07-17

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Asunercept治疗COVID-19：已在欧洲及俄罗斯开展II期临床试验

2020-11-09

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

IMU-838联合Oseltamivir治疗中重度COVID-19的II期临床试验：首位患者已入组

2021-06-01

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

免疫应答率100%！陈薇院士团队柳叶刀报告全球新冠疫苗I期临床试验结果

2021-01-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

间充质样细胞产品PLX治疗COVID-19：II期临床即将开展

2020-09-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

阿斯利康的IL-5受体单抗Fasenra：III期临床证实在嗜酸性哮喘中具有强大疗效

2021-01-24

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet：4价登革热疫苗TAK-003II期临床效果显著

2020-08-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

AAIC 2020：II期临床证实重组GM-CSF对阿尔茨海默氏症有治疗潜力

2020-09-08

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

学术前沿| 天津总医院杨学军团队发现原研新药ACT001抑制胶质瘤生长新机制 II期临床试验将启动

2020-06-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

挑战25年来的共识！阿尔兹海默症疫苗即将开展III期临床，这家公司剑指tau蛋白阿喀琉斯之踵

2021-05-25

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

口服溃疡性结肠炎新药Brilacidin的I期临床试验

2020-11-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

IDWeek 2020：肺炎链球菌疫苗ASP3772的I期临床数据，即将揭晓

2021-10-03

科室
- - 订阅+
  - 更多科室
工具
服务